Entropy Neurodynamics hopes that an expected FDA breakthrough drug approval for depression will pave the way for its own psychedelic therapy.
Tryptamine Therapeutics ( (AU:ENP)) has issued an update. Entropy Neurodynamics Limited has successfully completed the first patient dosing in its clinical trial for treating Binge Eating Disorder ...
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat ...
Hosted on MSN
Entropy Neurodynamics secures $847,186 R&D tax refund to advance psychedelic therapy trials
Tryptamine Therapeutics ( (AU:ENP)) has shared an update. Entropy Neurodynamics has received an $847,186 cash refund under Australia’s R&D Tax Incentive for its FY24 eligible research and development ...
The latest update is out from Tryptamine Therapeutics ( (AU:ENP) ).
An announcement from Tryptamine Therapeutics ( (AU:ENP)) is now available. Entropy Neurodynamics Limited has applied for quotation on the ASX of 1,200,000 new ordinary fully paid shares under code ENP ...
Our mission is to support our patients with mental or neurological disorders from the initial diagnostic to the end of the intervention, offering them state of the art technology to evaluate and treat ...
What is the current share price of Entropy Neurodynamics Limited (ENP)? Entropy Neurodynamics Limited's (ENP) current share price is $0.03. This constitutes a price movement of 2.86% when compared to ...
As of 12:35:26 pm AEST. Market open.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results